First-episode Psychosis Clinical Trial
Official title:
High Intensity Interval Training to Prevent Weight Gain in Patients With a First-episode Psychosis: a Randomized Clinical Trial
This study aims to estimate the effect of a 3-month High Intensity Interval Training on antipsychotic-induced weight gain in patients with a first episode of psychosis, as well as to determine whether these effects are maintained 9 months after the intervention has ended.
Status | Not yet recruiting |
Enrollment | 48 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Age =18 years and =40 years. - Treatment with antipsychotic medication =6 weeks. - Diagnosis of First Episode Psychosis, for inclusion in the ITPCan Clinical Program. Exclusion Criteria: - Pregnancy or breastfeeding - Poorly controlled diabetes. - Moderate or severe intellectual disability. - Current High Intensity Interval Training program. - Any systematic disease that contraindicates High Intensity Interval Training. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Intervención Temprana en Psicosis de Cantabria (ITPCan) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in weight gain induced by antipsychotic treatment in patients with a first episode of psychosis with a 12-week High Intensity Interval Training. | 12 weeks | ||
Primary | Change in weight gain induced by antipsychotic treatment in patients with a first episode of psychosis at 9 months after finishing the intervention. | 9 months post-intervention | ||
Secondary | Change in the lipid metabolism: triglycerides levels, total cholesterol levels, HDL cholesterol levels and LDL cholesterol levels. | Dyslipidemia is an abnormal amount of lipids (e.g.,triglycerides, cholesterol and/or fat phospholipids) in the blood.
The normal triglyceride level is between 30 and 150 mg/dL. The normal HDL cholesterol level is between 40 and 60 mg/dL. |
12 weeks and 9 months post-intervention | |
Secondary | Change in abdominal obesity measured by waist circumference. | Abdominal obesity, also known as central obesity, is when excessive abdominal fat around the stomach and abdomen has built up to the extent that it is likely to have a negative impact on health.
Men are considered to be at high risk from abdominal obesity if their waist measurements are 102 cm or higher, while women are considered to be at high risk if their waist measurements are 88 cm or higher. |
12 weeks and 9 months post-intervention | |
Secondary | Change in glycemic measured by fasting plasma glucose, glycosylated hemoglobin HbA1c and insulin. | Hyperglycemia, or high blood sugar (also spelled hyperglycaemia) is a condition in which an excessive amount of glucose circulates in the blood plasma.
A subject with a consistent range between 100-126 mg/dl is considered hyperglycemic, while above 126 mg/dl is generally held to have diabetes. |
12 weeks and 9 months post-intervention | |
Secondary | Change in hypertension measured by blood pressure. | Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long term medical condition in which the blood pressure in the arteries is persistently elevated.
Blood pressure is expressed by two measurements, the systolic and diastolic pressures, which are the maximum and minimum pressures, respectively. Normal blood pressure at rest is within the range of 100-130 millimeters mercury (mmHg) systolic and 60-85 mmHg diastolic. |
12 weeks and 9 months post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02319746 -
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
|
N/A | |
Completed |
NCT04248517 -
Using mHealth to Optimize Pharmacotherapy Regimens
|
N/A | |
Not yet recruiting |
NCT05384392 -
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
|
N/A | |
Not yet recruiting |
NCT05967195 -
Trial to Increase FEP Attendance
|
Early Phase 1 | |
Recruiting |
NCT02334904 -
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
|
N/A | |
Completed |
NCT03962348 -
Clinical Interviews With Detainees With Early Psychosis
|
N/A | |
Recruiting |
NCT04368039 -
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
|
N/A |